The life sciences industry, and big pharma in particular, has long favoured an integrated approach to D&D because of the importance of intellectual property to the company. In moving rapidly towards outsourcing, is it possible they are actually enabling future competitors rather than partners to grow up around them?
The possibility certainly exists. Forty five percent of survey respondents believe the largest CROs are developing sufficient competencies to become competitors of traditional pharmaceutical businesses in the near future; only 37% disagree. Moreover, 40% of respondents from potential CRO clients believe that a significant risk of outsourcing is that it allows a potential competitor to develop capacities; only 16% think this risk is not significant.